Windtree Therapeutics | ClinicalTrials HQ

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C	Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder	Active, not recruiting	Phase 1 / Phase 2	2025-08-20		NCT05975021
TH1902 in Patients With Advanced Solid Tumors	Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cutaneous melanoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hormone receptor-positive breast cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, small cell lung carcinoma, thyroid gland disorder, thyroid tumor, triple-negative breast carcinoma, uterine disorder	Active, not recruiting	Phase 1	2025-04-15		NCT04706962